10XYZ Holdings LP Amends Citius Oncology Filing

TL;DR

10XYZ Holdings LP updated their Citius Oncology stake filing as of 8/15/24.

AI Summary

10XYZ Holdings LP, formerly known as TenX Keane Acquisition, has filed an amendment (SC 13D/A) on August 15, 2024, regarding their holdings in Citius Oncology, Inc. The filing indicates a change in the date as of which the information is current to August 15, 2024. The company's business address is 420 Lexington Avenue, Suite 2446, New York, NY 10170.

Why It Matters

This amendment to a Schedule 13D filing signals a potential shift in significant ownership or control of Citius Oncology, Inc., which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant stake changes, which can lead to increased volatility and potential activist investor involvement.

Key Numbers

• 20240815 — Filing Date (Date of the SC 13D/A amendment filing)
• 20210315 — Name Change Date (Date Citius Oncology, Inc. changed its name from TenX Keane Acquisition)

Key Players & Entities

• 10XYZ Holdings LP (company) — Filing entity
• Citius Oncology, Inc. (company) — Subject company
• TenX Keane Acquisition (company) — Former name of 10XYZ Holdings LP
• Taylor Zhang (person) — Person authorized to receive notices

FAQ

Key Financial Figures

• $0.0001 — nc. (Name of Issuer) Common Shares, $0.0001 par value per share (Title of Class o
• $12.00 — e Issuer Common Stock equals or exceeds $12.00 per share for any 20 trading days withi

Filing Documents

• formsc13da.htm (SC 13D/A) — 56KB
• ex99-1.htm (EX-99.1) — 809KB
• ex99-2.htm (EX-99.2) — 37KB
• ex99-3.htm (EX-99.3) — 158KB
• 0001493152-24-032563.txt ( ) — 1061KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. The responses of the Reporting Person to Rows (7) through (13) of its cover pages to this Statement are incorporated herein by reference. (e) As a result of the Merger Agreement in Item 4, the Reporting Persons ceased to be the beneficial owner of more than five percent (5%) of the class of securities of the Company on August 12, 2024. The filing of this Amendment No. 1 represents the final amendment to the Initial Schedule 13D and constitutes an exit filing for the Reporting Person. Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. Merger Agreement The information set forth in Item 4 of this Amendment No. 1 with respect to the Merger Agreement is hereby incorporated by reference. CUSIP No. 17331Y109 Page 5 of 6 Pages Amended & Restated Registration Rights Agreement Concurrently with the completion of the Business Combination, the Issuer, the Sponsor, and Citius Pharma entered into the Amended & Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”). Pursuant to the A&R Registration Rights Agreement, the holders of Registrable Securities (as such term is defined in the A&R Registration Rights Agreement) will be entitled to up to three demand registrations, which will require the Issuer to effect the registration of all Registrable Securities as requested by the holders within 60 days of receipt of such demand registration. In addition, the holders of Registrable Securities have certain customary “piggyback” registration rights with respect to registration statements filed subsequent to the completion of the Business Combination. Additionally, the Sponsor and Citius Pharma have restrictions on transferring Issuer Common Stock (or any security convertible into, or exercisable or exchangeable for Issuer Common Stock) beginning at Closing until the date that is six months after Closing; provided that

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. Date: August 14, 2024 10XYZ Holdings LP By: /s/ Taylor Zhang Name: Taylor Zhang Title: Manager

View Full Filing

View this SC 13D/A filing on SEC EDGAR